...
首页> 外文期刊>Frontiers in Molecular Biosciences >Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer
【24h】

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer

机译:鉴定DNA修复基因签名及建立预测前列腺癌生物化学 - 复制存活的预后探测器

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The incidence of prostate cancer (PCa) is high and increasing worldwide. The prognosis of PCa is relatively good, but it is important to identify the patients with a high risk of biochemical recurrence (BCR) so that additional treatment could be applied. Method: Level 3 mRNA expression and clinicopathological data were obtained from The Cancer Genome Atlas (TCGA) to serve as training data. The GSE84042 dataset was used as a validation set. Univariate Cox, lasso Cox, and stepwise multivariate Cox regression were applied to identify a DNA repair gene (DRG) signature. The performance of the DRG signature was assessed based on Kaplan–Meier curve, receiver operating characteristic (ROC), and Harrell's concordance index (C-index). Furtherly, a prognostic nomogram was established and evaluated likewise. Results: A novel four DRG signature was established to predict BCR of PCa, which included POLM, NUDT15, AEN, and HELQ. The ROC and C index presented good performance in both training dataset and validation dataset. The patients were stratified by the signature into high- and low-risk groups with distinct BCR survival. Multivariate Cox analysis revealed that the DRG signature is an independent prognostic factor for PCa. Also, the DRG signature high-risk was related to a higher homologous recombination deficiency (HRD) score. The nomogram, incorporating the DRG signature and clinicopathological parameters, was able to predict the BCR with high efficiency and showed superior performance compared to the model that consisted of only clinicopathological parameters. Conclusion: Our study identified a DRG signature and established a prognostic nomogram, which were reliable in predicting the BCR of PTC. This model could help with individualized treatment and medical decision making.
机译:背景:前列腺癌(PCA)的发病率高,全世界增加。 PCA的预后是相对较好的,但重要的是鉴定生物化学复发(BCR)风险很高的患者,以便应用额外的治疗方法。方法:从癌症基因组Atlas(TCGA)获得3级mRNA表达和临床病理数据以作为培训数据。 GSE84042数据集用作验证集。仅应用单变量COX,套索COX和逐步多变量COX回归以鉴定DNA修复基因(DRG)签名。基于Kaplan-Meier曲线,接收器操作特征(ROC)和Harrell的一致性索引(C-Index)评估DRG签名的性能。此外,同样建立和评估预后的NOM图。结果:建立了一个新的四个DRG签名,以预测PCA的BCR,包括POLM,NUDT15,AEN和HELQ。 ROC和C索引在训练数据集和验证数据集中呈现出良好的性能。患者通过签名分析为具有明显的BCR存活率的高风险群体。多元COX分析显示DRG签名是PCA的独立预后因素。此外,DRG签名高风险与较高的同源重组缺乏(HRD)得分有关。纳入图表,掺入DRG签名和临床病理学参数的NOM图能够以高效率预测BCR,与仅由临床病理参数组成的模型相比,表现出优异的性能。结论:我们的研究确定了DRG签名并建立了预后的载体,可在预测PTC的BCR方面是可靠的。该模型可以帮助个性化治疗和医学决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号